Denali Therapeutics Inc [DNLI] stock is trading at $24.10, up 0.04%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DNLI shares have gain 12.30% over the last week, with a monthly amount glided 9.55%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Denali Therapeutics Inc [NASDAQ: DNLI] stock has seen the most recent analyst activity on December 13, 2023, when Citigroup initiated its Buy rating and assigned the stock a price target of $32. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $38 on September 06, 2023. SVB Securities initiated its recommendation with a Outperform and recommended $50 as its price target on January 30, 2023. In a note dated November 02, 2022, BTIG Research upgraded an Buy rating on this stock but restated the target price of $38.
Denali Therapeutics Inc [DNLI] stock has fluctuated between $14.56 and $28.75 over the past year. Currently, Wall Street analysts expect the stock to reach $91 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $24.10 at the most recent close of the market. An investor can expect a potential return of 277.59% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
Denali Therapeutics Inc [NASDAQ:DNLI] reported sales of 295.39M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.82% with Operating Profit Margin at 21.56%, Pretax Profit Margin comes in at 14.21%, and Net Profit Margin reading is 14.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.11 and Total Capital is -0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.68 points at the first support level, and at 23.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.70, and for the 2nd resistance point, it is at 25.30.
Ratios To Look Out For
For context, Denali Therapeutics Inc’s Current Ratio is 11.79. Further, the Quick Ratio stands at 11.79, while the Cash Ratio is 0.73. Considering the valuation of this stock, the price to sales ratio is 11.64, the price to book ratio is 2.36.
Transactions by insiders
Recent insider trading involved Krognes Steve E., Director, that happened on Jul 01 ’24 when 30000.0 shares were sold. Director, SATO VICKI L completed a deal on Jul 01 ’24 to sell 3080.0 shares. Meanwhile, Director Krognes Steve E. sold 688.0 shares on Jun 13 ’24.
